US Onychomycosis Market Research Report- Forecast To 2027

US Onychomycosis Information, by types (distal subungual onychomycosis (dso), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), endonyx onychomycosis (EO), and others) - Forecast to 2027

ID: MRFR/Pharma/1895-CR | April 2017 | Region: Global | 30 pages

Onychomycosis Market Scenario:


Onychomycosis is a contagious disease of the nails that causes staining, thickening, and partition from the nail bed. Onychomycosis happens in 10% of the all-inclusive population, 20% of people older than 60 years, and half of those older than 70 years. It is brought about by an assortment of organisms, however most cases are brought on by dermatophytes. The US market for Onychomycosis is expected to reach high market figures by the end of the forecasted period and is expected to grow at a CAGR of 6.4%


Segments:


US Onychomycosis market has been segmented on the basis of types which comprises of distal subungual onychomycosis (dso), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), endonyx onychomycosis (EO), and others.


Regional Analysis:


The US market for Onychomycosis is expected to grow at a CAGR of 6.4% and is expected to reach at more than US$ 5 billion by the end of the forecasted period. This is due to increasing ageing populations.


Key Players for Onychomycosis Market: 


Some of the key players in this market are: Anacor Pharmaceuticals, Johnson and Johnson, Novartis, Valeant Pharmaceuticals


America



  • North America

  • US


The report for US Onychomycosis market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions


Study Objectives:



  • To provide detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Onychomycosis  market  

  • To provide insights about factors affecting the market growth

  • To analyze the Onychomycosis market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to United States.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by type, by application, by end users and its sub-segments

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the US Onychomycosis market.


Intended Audience



  • Onychomycosis drug manufacturers

  • Onychomycosis drug Suppliers

  • Pharmaceutical companies

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 5 Billion
  CAGR   6.4% (2016-2022)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   types
  Geographies Covered   U.S. and Canada
  Key Vendors   Anacor Pharmaceuticals, Johnson and Johnson, Novartis, Valeant Pharmaceuticals
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments
  Key Market Drivers   technological advancement, macro economical and governing factors


Speak to Analyst Ask for Customization

1 Introduction

1.1 Onychomycosis: An Overview

1.2 Scope of Study

1.2.1 Research Objective

1.3 Market Structure

1.4 Types of Onychomycosis

1.5 Signs and Symptoms

1.5.1 Symptoms of Onychomycosis Nail Infection Based on Subtype

1.6 Cause

1.7 Treatments for Onychomycosis

2 Research Methodolgy

2.1 Primary Research

2.2 Secondary Research

3 Market Dynamics

3.1 Growth Drivers

3.1.1 Rising Per-capita Healthcare Expenditure

3.1.2 Increasing Diabetic Patients

3.1.3 Increasing Prevalence of Peripheral Artery Disease (PAD)

3.2 Challenges

3.2.1 Low awareness

3.2.2 Side effects

4 US Onychomycosis

4.1 US Onychomycosis Market

4.1.1 US Onychomycosis Market By Prevalence

4.1.2 US Nail Care Market

4.2 US Jublia Drug Market

4.3 US Kerydin Drug market

4.4 US Generic Drugs Market

5 Competitive Landscape

5.1 Market Share Analysis

6 Company Profile

6.1 Novartis

6.1.1 Overview

6.1.2 Product/Business Segment Overview

6.1.3 Financial Updates

6.1.4 Key Developments

6.2 Anacor Pharmaceuticals

6.2.1 Overview

6.2.2 Financial Updates

6.2.3 Key Developments

6.3 Johnson and Johnson

6.3.1 Overview

6.3.2 Product/Business Segment Overview

6.3.3 Financial Updates

6.3.4 Key Developments

6.4 Valeant Pharmaceuticals

6.4.1 Overview

6.4.2 Product/Business Segment Overview

6.4.3 Financial Updates

6.4.4 Key Developments

7 List of Tables

TABLE 1 TABLE FOR IDENTIFYING TYPES OF ONYCHOMYCOSIS 8

TABLE 2 US ONYCHOMYCOSIS MARKET, BY TYPES US$ (MILLION) 16

TABLE 3 US NAIL CARE MARKET, BY MAJOR DRUGS US$(MILLION) 17

TABLE 4 US JUBLIA DRUG MARKET, BY VALUE US$(MILLION) 18

TABLE 5 US JUBLIA DRUG MARKET, BY ASP ($) 18

TABLE 6 US JUBLIA DRUG MARKET BY VOLUME 19

TABLE 7 US KERYDIN DRUG MARKET BY VALUE US$ (MILLION) 19

TABLE 8 US KERYDIN DRUG MARKET, BY ASP ($) 19

TABLE 9 US KERYDIN DRUG MARKET BY VOLUME 20

TABLE 10 US GENERIC DRUG MARKET BY VALUE US$ (BILLION) 20

TABLE 11 US ONYCHOMYCOSIS MAJOR PLAYERS: 2020 (% SHARE) 21

8 List of Figures

FIGURE 1 RESEARCH PROCESS 11

FIGURE 2 US ONYCHOMYCOSIS MAJOR PLAYERS: 2020 (% SHARE) 21